Overview
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Background
Teicoplanin is a glycopeptide antibiotic consisting of a mixture of several compounds, five major (named teicoplanin A2-1 through A2-5) and four minor (named teicoplanin RS-1 through RS-4). All teicoplanins share a same glycopeptide core, teicoplanin A3-1, but differ in the length and conformation of side chains attached to their β-D-glucosamine moiety.
Indication
For the treatment of bacterial infections caused by susceptible microorganisms.
Associated Conditions
- Angina Pectoris
- Anginal Pain
- Bacteremia
- Bloodstream Infections (BSI)
- Bone and Joint Infections
- Clostridium Difficile
- Clostridium Difficile Infection (CDI)
- Community Acquired Pneumonia (CAP)
- Complicated Urinary Tract Infection
- Infective Endocarditis (IE)
- Lower Respiratory Tract and Lung Infections
- Non-complicated Skin and Soft Tissue Infections
- Nosocomial Pneumonia
- Peritonitis
- Skin and Soft Tissue Infections (SSTIs)
- Urinary Tract Infection
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2025/02/10 | Not Applicable | Not yet recruiting | |||
2023/06/22 | Phase 4 | Recruiting | |||
2020/04/30 | Phase 4 | Completed | |||
2020/04/10 | Phase 3 | UNKNOWN | |||
2019/11/25 | Phase 1 | Completed | |||
2019/07/01 | Phase 4 | Terminated | |||
2017/01/13 | N/A | UNKNOWN | |||
2016/01/11 | Not Applicable | Recruiting | |||
2013/12/23 | Phase 4 | Completed | |||
2013/03/21 | Phase 2 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| No FDA approvals found for this drug. | |||||
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| Teicoplanin for Injection | 国药准字H20253100 | 化学药品 | 注射剂 | 1/8/2025 | |
| Teicoplanin for Injection | 国药准字H20253606 | 化学药品 | 注射剂 | 3/11/2025 | |
| Teicoplanin for Injection | 国药准字H20253762 | 化学药品 | 注射剂 | 4/1/2025 | |
| Teicoplanin for Injection | 国药准字H20123376 | 化学药品 | 注射剂 | 10/17/2022 | |
| Teicoplanin for Injection | 国药准字H20123375 | 化学药品 | 注射剂 | 10/17/2022 | |
| Teicoplanin for Injection | 国药准字H20040387 | 化学药品 | 注射剂 | 4/9/2020 | |
| Teicoplanin for Injection | 国药准字HJ20160586 | 化学药品 | 注射剂 | 8/1/2023 | |
| Teicoplanin for Injection | 国药准字HJ20160587 | 化学药品 | 注射剂 | 8/1/2023 | |
| Teicoplanin for Injection | 国药准字H20249218 | 化学药品 | 注射剂 | 10/29/2024 | |
| Teicoplanin for Injection | 国药准字H20249206 | 化学药品 | 注射剂 | 10/29/2024 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| TEICOPLANIN MEDSURGE teicoplanin 400mg powder for injection vial with diluent ampoule | 389258 | Medicine | A | 6/28/2023 | |
| TARGOCID teicoplanin 400mg injection | 47886 | Medicine | A | 2/22/1994 | |
| TEICOPLANIN SANDOZ teicoplanin 400mg powder for injection vial with diluent ampoule | 157812 | Medicine | A | 8/11/2010 | |
| TEICOPLANIN SXP teicoplanin 400 mg powder for injection with diluent ampoule | 259192 | Medicine | A | 6/7/2017 | |
| TEICOPLANIN MEDICIANZ teicoplanin 400mg powder for injection vial with diluent ampoule | 389256 | Medicine | A | 6/28/2023 |